Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1447-1454

  Eber, Bernd ^a   Lautsch, Dominik ^b,c   Fauer, Christiane ^c   Drexel, Heinz ^b,d,e   Pfeiffer, Karl Peter ^f   Traindl, Otto ^g   Pichler, Max ^h  

^a Klinikum Kreuzschwestern Wels   (Austria)

^b PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^c Merck Sharp and Dohme Argentina Inc   (Argentina)

^d Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f University of Applied Sciences   (Austria)

^g Landesklinikum Weinviertel ^*  (Austria)

^h PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Cholesterol; Ezetimibe; Guidelines; Statins; Target attainment

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; PRACTICE GUIDELINE; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDIES; RISK FACTORS;

EID: 84866638330     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.717919     Document Type: Article

References (28)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
2. British Heart Foundation, 2005: European cardiovascular disease statistics. British Heart Foundation, London
3. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932-40
4. Kotseva K, Wood D, De Backer, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373:929-40
5. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur Heart J 2007;28:2375-414
6. Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(Suppl 1):S1-44
7. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81
8. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011;377:2181-92
9. Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events-results of the dyslipidemia international study (DYSIS). Wien Klin Wochenschr 2011;123:611-17
10. Huber K, Roden M. Lipidprofil und Therapiestatus in der Sekundä rprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in Ö sterreich. Wien Klin Wochenschr 2008;120:558-65
11. Foeger B, Patsch Jr. LDL-Cholesterin in der Sekundä rprä vention: Zielwert-Erreichung unter Lipidsenkern in Praxis und Spital in Ö sterreich (ZIEL). Wien Klin Wochenschr 2011;123:21-7
12. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34
13. Grundy SM, Cleeman JI, CNB Merz, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39
14. Pijlmana H, Huijgenb R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209:189-94
15. Kannel WB. Status of risk factors and their consideration in antihypertensive therapy. Am J Cardiol 1987;59:80-90A
16. Saely CH, Eber B, Pfeiffer KP, et al. Low serum LDL cholesterol in patients with type 2 diabetes. An analysis on two different patient populations. Int J Cardiol 2010;144:394-8
17. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S180-8
18. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hyper-cholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102:1489-94
19. Ben-Yehuda O, Wenger NK, Constance C, et al. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. J Geriatric Cardiol 2011;8:1-11
20. McCormack T, Harvey P, Gaunt R, et al. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010;64: 1052-61
21. Roeters van Lennep HW, Liem AH, Dunselman PHJM, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008;24:685-94
22. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and toler-ability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
23. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011;365:2250-1
24. European Medical Agency. Drug Label Zocord. http://www.ema.europa.eu/ docs/de-DE/document-library/Referrals-document/Zocord-30/WC500010253. pdf, accessed July 13 2012
25. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87
26. Bogiatzi C, Spence JD. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke 2012;43:1153-5. [Epub 2012 Jan 5]
27. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function. J Am Coll Cardiol 2009;54:1787-94
28. FDA Consumer Health Information. FDA: limit use of 80 mg simvastatin. US Food and Drug Administration June 2011. www.fda.gov/consumer